Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation

Trial Profile

Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Mar 2017

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Atrial fibrillation; Embolism; Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms XANTUS
  • Sponsors Bayer
  • Most Recent Events

    • 16 Nov 2016 Results of a sub-study (XANTUS-ACTS) presented at the 89th Annual Scientific Sessions of the American Heart Association
    • 16 Nov 2016 Results presented at the 89th Annual Scientific Sessions of the American Heart Association
    • 01 Oct 2016 Results of sub study published in the Clinical Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top